Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities

Clinical and Translational Science

Volumn 9, Issue 2, 2016, Pages 89-104

  Morrissey, Km ^a   Yuraszeck, Tm ^b   Li, C C ^a   Zhang, Y ^b   Kasichayanula, S ^b  

^a GENENTECH INC   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALECTINIB; ALEMTUZUMAB; ALPHA INTERFERON; ATEZOLIZUMAB; BEVACIZUMAB; BLINATUMOMAB; BRENTUXIMAB VEDOTIN; CANCER VACCINE; CETUXIMAB; COBIMETINIB; DACARBAZINE; DARATUMUMAB; DEXAMETHASONE; DURVALUMAB; ELOTUZUMAB; EPACADOSTAT; ERLOTINIB; IBRITUMOMAB TIUXETAN; IPILIMUMAB; LENALIDOMIDE; NIVOLUMAB; OFATUMUMAB; PEMBROLIZUMAB; RITUXIMAB; SIPULEUCEL T; TALIMOGENE LAHERPAREPVEC; TICILIMUMAB; TRASTUZUMAB; UNINDEXED DRUG; VEMURAFENIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN PRESENTATION; BLADDER CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL THERAPY; CHRONIC LYMPHATIC LEUKEMIA; COLITIS; COLORECTAL CANCER; DIARRHEA; DRUG APPROVAL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEAD AND NECK CANCER; HISTORY OF MEDICINE; HODGKIN DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSURVEILLANCE; KIDNEY CANCER; MELANOMA; METASTATIC MELANOMA; MULTIPLE MYELOMA; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; OVARY CANCER; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; SMALL CELL LUNG CANCER; SOLID TUMOR; STOMACH CANCER; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT; ADVERSE EFFECTS; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; ONCOLOGY; SOCIAL CONTROL;

CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; IMMUNOTHERAPY; MEDICAL ONCOLOGY; NEOPLASMS; SOCIAL CONTROL, FORMAL;

EID: 84963674132     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/cts.12391     Document Type: Review

References (104)

1. Couzin-Frankel, J. Cancer immunotherapy. Science 342, 1432-1433 (2013).
2. Bray, F., Jemal, A., Grey, N., Ferlay, J. & Forman, D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol. 13, 790-801.
3. Kim, R., Emi, M. & Tanabe, K. Cancer immunoediting from immune surveillance to immune escape. Immunology 121, 1-14 (2007).
4. Chen, D.S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1-10 (2013).
5. Beatty, G.L. & Gladney, W.L. Immune escape mechanisms as a guide for cancer immunotherapy. Clin. Cancer Res. 21, 687-692 (2015).
6. Nobelprize.org Emil von Behring: The Founder of Serum Therapy. Nobel Media AB Web. 3 Dec 2015. (2014).
7. McCarthy, E.F. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthopaed. J. 26, 154-158 (2006).
8. Galluzzi, L. et al. Classification of current anticancer immunotherapies. Oncotarget 5, 12472-12508 (2014).
9. Pardoll, D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012).
10. Nagorsen, D. & Baeuerle, P.A. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp. Cell Res. 317, 1255-1260 (2011).
11. Rosenberg, S.A., Yang, J.C. & Restifo, N.P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909-915 (2004).
12. Rosenberg, S.A., Restifo, N.P., Yang, J.C., Morgan, R.A. & Dudley, M.E. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8, 299-308 (2008).
13. Schumacher, T.N. & Schreiber, R.D. Neoantigens in cancer immunotherapy. Science 348, 69-74 (2015).
14. Adams, J.L., Smothers, J., Srinivasan, R. & Hoos, A. Big opportunities for small molecules in immuno-oncology. Nat. Rev. Drug Discov. 14, 603-622 (2015).
15. Escudier, B. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370, 2103-2111 (2007).
16. Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23-34 (2015).
17. Spranger, S. & Gajewski, T. Rational combinations of immunotherapeutics that target discrete pathways. J. Immunother. Cancer 1, 16 (2013).
18. European Medicines Agency (EMA). Committee for Medicinal Products for Human Use (CHMP), Guideline on Strategies to Identify and Mitigate Risks for First-in-Human Clinical Trials with Investigational Medicinal Products. (July 2007).
19. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP), Assessment Report: Opdivo (April 25, 2015).
20. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP), Assessment Report: Yervoy (ipilimumab). (May 19, 2011).
21. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP), Assessment Report: Keytruda. (May 21, 2015).
22. Dong, J.Q. et al. Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction. Clin. Pharmacokinet. 50, 131-142 (2011).
23. Stroh, M. et al. Challenges and opportunities for quantitative clinical pharmacology in cancer immunotherapy: something old, something new, something borrowed, and something blue. CPT Pharmacometrics Syst. Pharmacol. 4, 495-497 (2015).
24. Gibbs, J.P. Prediction of exposure-response relationships to support first-in-human study design. AAPS J. 12, 750-758 (2010).
25. Kochenderfer, J.N. et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119, 2709-2720 (2012).
26. Grupp, S.A. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509-1518 (2013).
27. Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Science Tramsl. Med. 3, 95ra 73 (2011).
28. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH Harmonized Tripartite Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals S9. (October 29, 2009).
29. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH Harmonized Tripartite Guideline: Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals S6 (R1). (July 16, 1997).
30. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH Harmonized Tripartite Guideline: Guidance on Nonclincal Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals M3(R2). (June 11, 2009).
31. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, Guidance for Industry: Preclinical Assessment of Investigational Cellular and Gene Therapy Products. (November 2013).
32. European Medicines Agency (EMEA) Note for Guidance on Nonclinical Evaluation for Anticancer Pharmaceuticals (December 2008).
33. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research (CBER), Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines (October 2011).
34. European Medicines Agency (EMA). Oncology Working Group, Guideline on the evaluation of anticancer medicinal products in man. (December 13, 2012).
35. Ministry of Health Labour and Welfare Grant for Expedited Review of Drugs and Other Products Project for Enhanced Practical Application of Innovative Drugs, M.D., and Regenerative Medicine Products Guidance Development Review Committee 2015 Guidance on Cancer Immunotherapy Development Early-Phase Clinical Studies - For Development of Safe and Effective Immunotherapy (January 30, 2015).
36. FDA Codevelopment of Two or More New Investigational Drugs for Use in Combination. (June 2013).
37. Mick, R. & Ratain, M.J. Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precision. J. Natl. Cancer Inst. 85, 217-223 (1993).
38. Mandrekar, S.J., Qin, R. & Sargent, D.J. Model-based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations: Methods and challenges. Stat. Med. 29, 1077-1083 (2010).
39. Brahmer, J.R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167-3175 (2010).
40. Topalian, S.L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
41. Patnaik, A. et al. Phase I study of pembrolizumab (MK-3475; Anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin. Cancer Res. 21, 4286-4293 (2015).
42. Callahan, M.K. & Wolchok, J.D. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J. Leuk. Biol. 94, 41-53 (2013).
43. Basch, E. et al. Patient-reported outcomes in cancer drug development and us regulatory review: Perspectives from industry, the food and drug administration, and the patient. JAMA Oncol. 1, 375-379 (2015).
44. Information, O.U.S.P. Opdivo Prescribing Information. Princeton, NJ: Bristol-Myers Squibb Company (Last updated: October 9, 2015).
45. Eggermont, A.M.M. et al. Adjuvant ipilimumab vs. placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 16, 522-530 (2015).
46. Postow, M.A. et al. Nivolumab and ipilimumab vs. ipilimumab in untreated melanoma. N. Engl. J. Med. 372, 2006-2017 (2015).
47. Puts, M.T.E. et al. Factors influencing adherence to cancer treatment in older adults with cancer: a systematic review. Ann. Oncol. (2013).
48. Wolchok, J.D. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412-7420 (2009).
49. Agrawal, S., Feng, Y., Roy, A., Kollia, G.D. & Lestini, B.J. Nivolumab dose selection: challenges, opportunities and lessons learned for cancer immunotherapy. J. Immunother. Cancer 3, 141 (2015).
50. Singh, I. et al. A Systems Pharmacology Model to Characterize the Effect of Blinatumomab in Patients With Adult B Precursor Acute Lymphoblastic Leukemia. Poster presented at the ASCPT annual meeting, Atlanta, GA (March 2014).
51. Feng, Y. et al. Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin. Cancer Res. 19, 3977-3986 (2013).
52. Feng, Y. et al. Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma. Br. J. Clin. Pharmacol. 78, 106-117 (2014).
53. Khoja, L., Butler, M.O., Kang, S.P., Ebbinghaus, S. & Joshua, A.M. Pembrolizumab. J. Immunother. Cancer 3, 36 (2015).
54. Chatterjee, M., Turner, D.C., Ahamadi, M., Alwis, Dinesh de, Elassaiss-Schaap, J., Freshwater, T., de Greef, R., Li, C., Mayawala, K., Stone, J., Kondic, A.Model-based analysis of the relationship between pembrolizumab exposure and efficacy in patients with melanoma and NSCLC: across indication comparison. PAGE 24 Abstr 3579 [www.page-meeting.org/?abstract=3579] (2015).
55. Sorger, Peter K (co-chair), S.R.B.A.c.-c., Darrell R. Abernethy, R.B.A., Kim L. R. Brouwer, Andrea Califano, David Z., D'Argenio, R.I., William J. Jusko, Richard Lalonde, Douglas A. Lauffenburger, Brian Shoichet, J.L.S., Shankar Subramaniam, Piet Van der Graaf and & Vicini, P. Quantitative and Systems Pharmacology in the Post-genomic Era: New Approaches to Discovering Drugs and Understanding Therapeutic Mechanisms An NIH White Paper by the QSP Workshop Group (October, 2011).
56. nd. Enhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case study. J. Immunother. Cancer 3, 27 (2015).
57. Huang, S.M. et al. Therapeutic protein-drug interactions and implications for drug development. Clin. Pharmacol. Ther. 87, 497-503 (2010).
58. Xu, Y. et al. Physiologically based pharmacokinetic model to assess the influence of blinatumomab-mediated cytokine elevations on cytochrome P450 enzyme activity. CPT: Pharmacometrics Syst.Pharmacol. 4, 507-515 (2015).
59. Mandema, J.W., Gibbs, M., Boyd, R.A., Wada, D.R. & Pfister, M. Model-based meta-analysis for comparative efficacy and safety: application in drug development and beyond. Clin. Pharmacol. Ther. 90, 766-769 (2011).
60. Wolchok, J.D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122-133 (2013).
61. Sanborn, R. et al. A phase I dose-escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) administered in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (Pts) with advanced refractory solid tumors. J. Clin. Oncol. 31 (2013).
62. Le Tourneau, C., Lee, J.J. & Siu, L.L. Dose escalation methods in phase I cancer clinical trials. J. Natl. Cancer Inst. 101, 708-720 (2009).
63. Harrington, J.A., Wheeler, G.M., Sweeting, M.J., Mander, A.P. & Jodrell, D.I. Adaptive designs for dual-agent phase I dose-escalation studies. Nat. Rev. Clin. Oncol. 10, 277-288 (2013).
64. Gandhi, L. et al. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J. Clin. Oncol. 32, 68-75 (2014).
65. Mandrekar, S.J. Dose-finding trial designs for combination therapies in oncology. J. Clin. Oncol. 32, 65-67 (2014).
66. Schadendorf, D. et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J. Clin. Oncol. 33, 1889-1894 (2015).
67. Garon, E.B. et al. Pembrolizumab for the Treatment of Non-SmallCell Lung Cancer. N. Engl. J. Med. 372, 2018-2028 (2015).
68. Cha, E., Wallin, J. & Kowanetz, M. PD-L1 inhibition with MPDL3280A for solid tumors. Semin. Oncol. 42, 484-487 (2015).
69. Herbst, R.S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563-567 (2014).
70. FDA approves Keytruda for advanced non-small cell lung cancer. FDA News Release http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm465444.htm (October 2, 2015).
71. Rizvi, N., Chaft, J., Balmanoukian, A., Goldberg, S.B., Sanborn, R.E., Steele, K.E., Rebelatto, M.C., Gu, Y., Karakunnel, J.J., Antonia, S. Tumor response from durvalumab (MEDI4736) +tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status. J. Immunother. Cancer 3, P 193 (2015).
72. Hamid, O. et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J. Tramsl. Med. 9, 204 (2011).
73. FDA approves first-of-its-kind product for the treatment of melanoma. FDA News Release (October 27, 2015).
74. Ledford, H. Cancer-fighting viruses near market. Nature 526, 622-623 (2015).
75. Lawrence, M.S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-218 (2013).
76. Rizvi, N.A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124-128 (2015).
77. Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189-2199 (2014).
78. Hijazi, Y. et al. Blinatumomab exposure and pharmacodynamic response in patients with non-Hodgkin lymphoma (NHL). abstract #3051 (ASCO Annual Meeting 2013).
79. Chen, L. & Flies, D.B. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 13, 227-242 (2013).
80. Gao, J., Bernatchez, C., Sharma, P., Radvanyi, L.G. & Hwu, P. Advances in the development of cancer immunotherapies. Trends Immunol. 34, 90-98 (2013).
81. Zhao, L., Ren, T.H. & Wang, D.D. Clinical pharmacology considerations in biologics development. Acta Pharmacol. Sin. 33, 1339-1347 (2012).
82. Pharmacokinetics in Drug Development: Regulatory and Development Paradigms, Vol. Vol 2. (American Association of Pharmaceutical Scientists, Bonate, P. and Howard, D. (eds) (2004)).
83. Kramps, T. & Probst, J. Messenger RNA-based vaccines: progress, challenges, applications. Wiley Interdiscipl. Rev. RNA 4, 737-749 (2013).
84. U.S. Department of Health and Human Services, Food and Drug Administration, & Center for Drug Evaluation and Research (CDER). C.f.B.E.a.R.C. Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products. (August 2014).
85. Opdivo(R) United States Prescribing Information [USPI]. (November 2015).
86. BLINCYTO(R) United States Prescribing Information [USPI]. (December 2014).
87. Statkevich, P. et al. Assessment of the immunogenicity of nivolumab (nivo) and ipilimumab (ipi) in combination and potential impact on safety and efficacy in patients with advanced melanoma. Clin. Pharmacol. Ther. 99, 10.1002/cpt.1310 (2016).
88. Zhu, L. et al. Model-based assessment of drug-drug interaction and immunogenicity on the pharmacokinetics (PK) of nivolumab and ipilimumab in combination in advanced melanoma patients. Clin. Pharmacol. Ther. 99, doi:10.1002/cpt1310 (2016).
89. Xu, Y. et al. Physiologically based pharmacokinetic model to assess the influence of blinatumomab-mediated cytokine elevations on cytochrome P450 enzyme activity. CPT Pharmacometrics Syst. Pharmacol. 4, 507-515 (2015).
90. Postow, M.A., Callahan, M.K. & Wolchok, J.D. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. (2015).
91. Gangadhar, T.C. & Vonderheide, R.H. Mitigating the toxic effects of anticancer immunotherapy. Nat. Rev. Clin. Oncol. 11, 91-99 (2014).
92. Villadolid, J. & Amin, A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl. Lung Cancer Res. 4, 560-575 (2015).
93. Maude, S.L., Barrett, D., Teachey, D.T. & Grupp, S.A. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 20, 119-122 (2014).
94. Ribas, A., Hodi, F.S., Callahan, M., Konto, C. & Wolchok, J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N. Engl. J. Med. 368, 1365-1366 (2013).
95. Weber, J.S., Kähler, K.C. & Hauschild, A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 30, 2691-2697 (2012).
96. Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517-2526 (2011).
97. Di Giacomo, A.M. et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol. 13, 879-886 (2012).
98. Beatty GL et al. Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2, 3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies. J. Clin. Oncol. 31, 3025 (2013).
99. Gibney, G. et al. Updated results from a phase 1/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma. The European Cancer Congress Vienna, Austria (September 25, 2015).
100. Gangadhar, T.C. et al. Preliminary results from a phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers. J. Immunother. Cancer 3 (2015).
101. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) Guidance for Industry: Biologics Clinical Trial End points for the Approval of Cancer Drugs and Biologics. (May 2007).
102. European Medicines Agency Guideline on the evaluation of anticancer medicinal products in man. (December 2012).
103. Keytruda(R) United States Prescribing Information [USPI], . (October 2015).
104. Hodi, F.S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).